Association between Proteinuria and Risk of Chronic Inflammatory Demyelinating Polyneuropathy/Multifocal Motor Neuropathy: A Nationwide Population-based Cohort Study Authors: Soonwook Kwon, Ye Bin Park, Kyung-Do Han, Hye Ryoun Jang, Seung Ho Choo, Dong Wook Shin, Ju-Hong Min Published: 2026 ABSTRACT BackgroundThis study aimed to determine whether proteinuria is associated with the subsequent development of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN).MethodsWe conducted a population-based retrospective cohort study using the Korean National Health Insurance Service database. Individuals aged ≥ 20 years who underwent national health screening in 2009 (N = 3,937,902) were followed until December 2020. Participants with a prior history of CIDP/MMN or diagnosis within one year of screening were excluded. Proteinuria was assessed via urine dipstick (positive ≥ 1+). The primary outcome was incident CIDP/MMN, defined by the concurrent presence of ICD-10 code G61.8 and Rare and Intractable Disease program code V126. Cox proportional hazards models examined the association, adjusting for potential confounders.ResultsAt baseline, 2.5% of individuals had proteinuria. During follow-up, 210 individuals developed CIDP/MMN. The incidence rate was significantly higher in those with proteinuria (1.44 per 100,000 person-years) than in those without (0.50 per 100,000 person-years). After adjustment for demographics, lifestyle, and comorbidities, proteinuria remained significantly associated with increased CIDP/MMN risk (adjusted hazard ratio 2.32; 95% confidence interval 1.35–4.03). This association was consistent across subgroups defined by sex, age, and chronic kidney disease.ConclusionProteinuria is associated with a modest risk of developing CIDP/MMN. These findings suggest possible shared immunopathologic mechanisms involving antigens or immune pathways common to both the kidney and peripheral nerves. Neurologic monitoring may be warranted in individuals with proteinuria. Introduction Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) are immune-mediated disorders of the peripheral nervous system, characterized by demyelination. CIDP affects both motor and sensory fibers, whereas MMN primarily involves motor nerves [1, 2]. Proteinuria is a clinical marker of renal dysfunction and has been reported in association with immune-mediated neuropathies [3, 4]. Since the 1970 s, Guillain-Barré syndrome has been described in patients with nephrotic syndrome, and subsequent studies have reported CIDP in patients with nephrotic syndrome [4–8]. Several reports in CIDP presented with proteinuria without overt nephrotic features, suggesting subclinical or early-stage renal involvement [9]. Recent cross-sectional studies have reported that nephrotic syndrome occurs in 3.4% to 15.3% of patients with CIDP. The most common histopathological finding was membranous glomerulonephritis [10, 11]. It is more frequently observed in autoimmune nodopathies associated with antibodies targeting nodal or paranodal proteins, including anti–contactin-1 (CNTN1) antibodies and anti-neurofascin (NF) antibodies [10, 12, 13]. These observations suggest a possible link between immune-mediated process affecting peripheral nerves and renal glomeruli. However, no epidemiologic studies have evaluated the association between proteinuria and CIDP/MMN, likely due to the rarity of these conditions. It also remains unclear whether proteinuria precedes the development of CIDP/MMN or occurs as a secondary phenomenon. Therefore, we aimed to investigate the association between proteinuria and CIDP/MMN using a nationwide, population-based cohort in South Korea. Methods Data Source This retrospective, nationwide, population-based cohort study was conducted using the KNHIS database, which is derived from the South Korean mandatory health insurance system operated by the Ministry of Health and Welfare of South Korea and covers more than 97% of the population [14]. The KNHIS database includes demographic information such as age, sex, income level, and region, as well as claims data with diagnosis codes defined according to the International Classification of Diseases, Tenth Revision (ICD-10). Additionally, all beneficiaries over the age of 40 and all company workers over the age of 20 are eligible for a biennial national health screening program [15]. Health screening data curated in the KNHIS database include anthropometric measurements (e.g., body weight, height, and waist circumference), laboratory tests (e.g., blood glucose, lipid profile, serum creatinine, liver function test, and urine analysis), and self-reported questionnaires assessing comorbidities, smoking status, alcohol consumption, physical activity, and family history [16]. The database also links to the national death registry to verify enrollee status. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB No. SMC-2025-04-084) and access to the database was approved by the KNHIS (NHIS-2025-09-1–084). The requirement for informed consent was waived due to the use of de-identified retrospective data. Study Population and Follow-up We identified 4,234,415 individuals aged ≥ 20 years who participated in the national health screening program in 2009 (Fig. 1). Individuals with a prior diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN) (N = 86), or with incomplete medical information (N = 286,382) were excluded. The operational definition of CIDP/MMN is provided in the Primary Outcome section. In addition, individuals who were diagnosed with CIDP/MMN or died within one year after the 2009 health screening were excluded (N = 10,045), resulting in a final cohort of 3,937,902 individuals. The cohort was followed from the date of the health screening in 2009 until December 31, 2020. Follow-up was censored at the time of CIDP/MMN diagnosis or death, whichever occurred first. Grouping by Proteinuria Proteinuria was assessed using a urine dipstick test conducted during the 2009 national health screening program. Although the urine protein-to-creatinine ratio and urine albumin-to-creatinine ratio offer more accurate quantification, they are not cost-effective in a national health screening program and require time-consuming confirmatory procedures. In contrast, the urine dipstick test is a simple and cost-effective test. Dipstick results were semi-quantitatively categorized as negative, trace, 1+, 2+, 3+, or 4 + based on the colorimetric changes corresponding to proteinuria concentration. In the present study, individuals were classified into four groups according to the degree of proteinuria: negative, trace, 1+, and ≥ 2+. Primary Outcome The primary outcome of this study was the incidence of newly developed CIDP/MMN during the follow-up period. The operational definition of CIDP/MMN was based on both the ICD-10 code (G61.8) and the Rare and Intractable Disease (RID) code (V126). To enhance diagnostic accuracy, follow-up was censored at the first date on which both codes were recorded. In South Korea, patients with CIDP/MMN are registered in the RID program, which subsidizes 90% of disease-related medical expenses [17–19]. Enrollment in this program is considered highly reliable, as it requires verification by qualified neurologists according to established diagnostic criteria and is typically conducted at tertiary referral hospitals equipped for comprehensive differential diagnosis. However, CIDP and MMN share the same ICD-10 and RID codes; it is therefore not possible to distinguish between the two diseases solely based on diagnostic codes. Therefore, patients diagnosed with either CIDP or MMN were analyzed together as CIDP/MMN. Variables Smoking status was classified as current (≥ 100 cigarettes in their lifetime and still smoking), ex-smoker (≥ 100 cigarettes in their lifetime but quit), or non-smoker (< 100 cigarettes in their lifetime). Alcohol consumption was categorized as heavy drinkers (≥ 30 g/day for men and ≥ 20 g/day for women), mild drinkers (< 30 g/day for men and < 20 g/day for women), and non-drinkers. Regular exercise was defined as engaging in vigorous physical activity for ≥ 20 min on ≥ 3 days per week or moderate-intensity physical activity for ≥ 30 min on ≥ 5 days per week. Low income was defined as the lowest quartile of insurance premium payment or eligibility for medical aid, serving as a proxy for socioeconomic status. Comorbidities were identified using self-reported questionnaires or data from the national health screening program [20]. Hypertension was defined by the presence of relevant ICD-10 codes (I10–13 or I15) and at least one antihypertensive prescription, or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg recorded during health screening. Diabetes mellitus was defined by an ICD-10 code (E10–14) and at least one anti-diabetic drug, or a fasting blood glucose level ≥ 126 mg/dL. Dyslipidemia was defined by an ICD-10 code (E78) and a prescription for a lipid-lowering medication, or total cholesterol ≥ 240 mg/dL. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2, or receipt of hemodialysis, peritoneal dialysis, or a kidney transplantation, based on RID codes V001, V003, or V005, respectively. Statistical Analysis Continuous variables are presented as mean ± standard deviation (SD), and categorical variables as number (percentage). Comparisons between groups were conducted using Student’s t-test or analysis of variance (ANOVA) for continuous variables, and the chi-square test for categorical variables. The incidence rate of CIDP/MMN was calculated as the number of events per 100,000 person-years. Cumulative incidence rates were compared between groups using the Kaplan–Meier method and the log-rank test. Crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, with proteinuria as the main exposure. The adjusted model included age and sex, an additional model further adjusted for income status, smoking status, alcohol consumption, regular exercise, and comorbidities including diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease as covariates. We assessed the events-per-variable ratio to evaluate potential overfitting. Subgroup analyses were performed according to age (< 65 vs. ≥65 years), sex, and the presence of chronic kidney disease. All statistical analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). A two-sided P-value < 0.05 was considered statistically significant. Results Baseline Characteristics Baseline characteristics of the study cohort are presented in Table 1. Among 3,937,902 individuals, 99,821 (2.5%) had a dipstick proteinuria of 1 + or higher. Compared to those without proteinuria, individuals with proteinuria had a similar sex distribution (P-value = 0.071) but were older (mean age 51.8 ± 14.37 vs. 47.1 ± 14.00, P-value < 0.001) and had a higher prevalence of comorbidities (P-value < 0.001). Table 1Baseline characteristics of the study populationTotal population (n = 3,937,902)P-valueProteinuria (-)Proteinuria (+)Number, n (%)3,838,081 (97.5%)99,821 (2.5%) Demographics Age, mean ± SD (years)47.1 ± 14.051.8 ± 14.4 < 0.001 20–643,342,759 (87.1)78,689 (78.8) < 0.001 ≥ 65495,322 (12.9)21,132 (21.2)Sex, n (%)0.071 Male2,093,703 (54.6)54,741 (54.8) Female1,744,378 (45.5)45,080 (45.2)Body mass index, mean ± SD (kg/m2)23.7 ± 3.224.4 ± 3.6< 0.001Smoking, n (%) None2,289,023 (59.6)59,379 (59.5)< 0.001 Ex-smoker548,985 (14.3)15,810 (15.8) Current1,000,073 (26.1)24,632 (24.7)Alcohol consumption, n (%) None1,980,668 (51.6)55,173 (55.3)< 0.001 Mild1,531,410 (39.9)34,790 (34.9) Heavy326,003 (8.5)9,858 (9.9) Regular exercise, n (%)689,115 (18.0)18,746 (18.8)< 0.001 Low-income level, n (%)746,207 (19.4)20,483 (20.5)< 0.001 Comorbidities Diabetes mellitus, n (%)317,211 (8.3)24,796 (24.8) < 0.001 Hypertension, n (%)955,376 (24.9)46,729 (46.8) < 0.001 Dyslipidemia, n (%)653,253 (17.0)29,180 (29.2) < 0.001 Chronic kidney disease, n (%)257,855 (6.7)16,967 (17.0) < 0.001 Key differences between groups are highlighted in boldContinuous variables are presented as mean ± SD and categorical variables as number (%) Table 1Baseline characteristics of the study populationTotal population (n = 3,937,902)P-valueProteinuria (-)Proteinuria (+)Number, n (%)3,838,081 (97.5%)99,821 (2.5%) Demographics Age, mean ± SD (years)47.1 ± 14.051.8 ± 14.4 < 0.001 20–643,342,759 (87.1)78,689 (78.8) < 0.001 ≥ 65495,322 (12.9)21,132 (21.2)Sex, n (%)0.071 Male2,093,703 (54.6)54,741 (54.8) Female1,744,378 (45.5)45,080 (45.2)Body mass index, mean ± SD (kg/m2)23.7 ± 3.224.4 ± 3.6< 0.001Smoking, n (%) None2,289,023 (59.6)59,379 (59.5)< 0.001 Ex-smoker548,985 (14.3)15,810 (15.8) Current1,000,073 (26.1)24,632 (24.7)Alcohol consumption, n (%) None1,980,668 (51.6)55,173 (55.3)< 0.001 Mild1,531,410 (39.9)34,790 (34.9) Heavy326,003 (8.5)9,858 (9.9) Regular exercise, n (%)689,115 (18.0)18,746 (18.8)< 0.001 Low-income level, n (%)746,207 (19.4)20,483 (20.5)< 0.001 Comorbidities Diabetes mellitus, n (%)317,211 (8.3)24,796 (24.8) < 0.001 Hypertension, n (%)955,376 (24.9)46,729 (46.8) < 0.001 Dyslipidemia, n (%)653,253 (17.0)29,180 (29.2) < 0.001 Chronic kidney disease, n (%)257,855 (6.7)16,967 (17.0) < 0.001 Key differences between groups are highlighted in boldContinuous variables are presented as mean ± SD and categorical variables as number (%) Baseline characteristics of the study population Key differences between groups are highlighted in bold Continuous variables are presented as mean ± SD and categorical variables as number (%) Proteinuria and the Risk of CIDP/MMN During a mean follow-up period of 10.1 ± 1.27 years, 210 individuals were diagnosed with CIDP or MMN (Fig. 1). The incidence rate of CIDP/MMN was 0.50 per 100,000 person-years in individuals without proteinuria and 1.44 per 100,000 person-years in those with proteinuria (Table 2). After adjusting age and sex, the HR for CIDP/MMN in individuals with proteinuria was 2.46 (95% CI 1.43–4.24; EPV ratio 70). The crude model showed a similar association (HR 2.89, 95% CI 1.68–4.97; EPV ratio 210) and the results remained consistent after further adjustment for additional covariates (HR 2.32, 95% CI 1.35–4.03; EPV ratio 15), with a relatively low EPV ratio. Kaplan–Meier analysis showed that the cumulative incidence of CIDP/MMN increased over time in both groups, with a higher cumulative incidence in individuals with proteinuria throughout the follow-up period and a progressively widening difference between the groups. (Fig. 2).Fig. 1Flow chart of study population enrollmentCIDP/MMN, chronic inflammatory demyelinating polyradiculoneuropathy/multifocal motor neuropathy. Flow chart of study population enrollment CIDP/MMN, chronic inflammatory demyelinating polyradiculoneuropathy/multifocal motor neuropathy. Kaplan–Meier curves of the cumulative incidence of CIDP/MMN CIDP/MMN, chronic inflammatory demyelinating polyradiculoneuropathy/multifocal motor neuropathy. Table 2Crude and adjusted hazard ratios for CIDP/MMN based on proteinuria statusProteinuria N CIDP/MMNDuration,yearsIncidence rate,per 100,000person-yearsHazard ratio (95% confidence intervals)CrudeAdjusted*Negative3,838,08119638,853,992.30.501 (Ref.)1 (Ref.)Positive99,82114972,285.91.442.89 (1.68–4.97)2.46 (1.43–4.24)Total3,937,90221039,826,278.20.53N number, CIDP/MMN chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy*Adjusted for age and sexThe events-per-variable ratio was 210 in the crude model (210/1) and 70 in the adjusted model (210/3) Table 2Crude and adjusted hazard ratios for CIDP/MMN based on proteinuria statusProteinuria N CIDP/MMNDuration,yearsIncidence rate,per 100,000person-yearsHazard ratio (95% confidence intervals)CrudeAdjusted*Negative3,838,08119638,853,992.30.501 (Ref.)1 (Ref.)Positive99,82114972,285.91.442.89 (1.68–4.97)2.46 (1.43–4.24)Total3,937,90221039,826,278.20.53N number, CIDP/MMN chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy*Adjusted for age and sexThe events-per-variable ratio was 210 in the crude model (210/1) and 70 in the adjusted model (210/3) Crude and adjusted hazard ratios for CIDP/MMN based on proteinuria status N number, CIDP/MMN chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy *Adjusted for age and sex The events-per-variable ratio was 210 in the crude model (210/1) and 70 in the adjusted model (210/3) Subgroup Analyses Subgroup analyses showed no significant modification of the association between proteinuria and CIDP/MMN by age or sex, with hazard ratios in each subgroup consistent with those in the overall population (Table 3). However, among individuals with CKD, those with proteinuria were at increased risk of CIDP/MMN compared to those without proteinuria (6 events vs. 19 events; aHR 4.47, 95% CI 1.78–11.24). Several subgroups contained a small number of events, fewer than 10 cases, resulting in wide confidence intervals and limited precision of the estimates. Therefore, the results of subgroup analyses should be considered exploratory and interpreted with caution. Table 3Subgroup analyses of the CIDP/MMN risk stratified by age, sex, and chronic kidney diseaseSubgroupProteinuriaNCIDP/MMNDuration,yearsIncidence rate,per 100,000person-yearsHazard ratio (95% CI)CrudeAdjusted*Age, years< 65No3,342,75914934,236,752.40.441 (Ref.)1 (Ref.)Yes78,68910792,833.41.262.91 (1.54–5.53)2.47 (1.29–4.72)≥ 65No495,322474,617,239.91.021 (Ref.)1 (Ref.)Yes21,1324179,452.52.232.26 (0.82–6.28)2.00 (0.72–5.58)P for interaction0.681SexMaleNo2,093,70313821,067,224.40.661 (Ref.)1 (Ref.)Yes54,74110524,459.81.912.96 (1.56–5.62)2.30 (1.20–4.40)FemaleNo1,744,3785817,786,767.90.331 (Ref.)1 (Ref.)Yes45,0804447,826.20.892.76 (1.00–7.60)2.38 (0.86–6.57)P for interaction0.910ChronicKidneydiseaseWithout CKDNo3,580,22617736,318,358.10.491 (Ref.)1 (Ref.)Yes82,8548820,603.40.972.02 (0.99–4.10)1.75 (0.86–3.56)With CKDNo257,855192,535,634.20.751 (Ref.)1 (Ref.)Yes16,9676151,682.53.965.46 (2.18–13.66)4.47 (1.78–11.24)P for interaction0.0930.112N number, CIDP/MMN chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy*Adjusted for age, sex, body mass index, smoking, alcohol consumption, regular exercise, low-income, diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease Table 3Subgroup analyses of the CIDP/MMN risk stratified by age, sex, and chronic kidney diseaseSubgroupProteinuriaNCIDP/MMNDuration,yearsIncidence rate,per 100,000person-yearsHazard ratio (95% CI)CrudeAdjusted*Age, years< 65No3,342,75914934,236,752.40.441 (Ref.)1 (Ref.)Yes78,68910792,833.41.262.91 (1.54–5.53)2.47 (1.29–4.72)≥ 65No495,322474,617,239.91.021 (Ref.)1 (Ref.)Yes21,1324179,452.52.232.26 (0.82–6.28)2.00 (0.72–5.58)P for interaction0.681SexMaleNo2,093,70313821,067,224.40.661 (Ref.)1 (Ref.)Yes54,74110524,459.81.912.96 (1.56–5.62)2.30 (1.20–4.40)FemaleNo1,744,3785817,786,767.90.331 (Ref.)1 (Ref.)Yes45,0804447,826.20.892.76 (1.00–7.60)2.38 (0.86–6.57)P for interaction0.910ChronicKidneydiseaseWithout CKDNo3,580,22617736,318,358.10.491 (Ref.)1 (Ref.)Yes82,8548820,603.40.972.02 (0.99–4.10)1.75 (0.86–3.56)With CKDNo257,855192,535,634.20.751 (Ref.)1 (Ref.)Yes16,9676151,682.53.965.46 (2.18–13.66)4.47 (1.78–11.24)P for interaction0.0930.112N number, CIDP/MMN chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy*Adjusted for age, sex, body mass index, smoking, alcohol consumption, regular exercise, low-income, diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease Subgroup analyses of the CIDP/MMN risk stratified by age, sex, and chronic kidney disease Chronic Kidney disease N number, CIDP/MMN chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy *Adjusted for age, sex, body mass index, smoking, alcohol consumption, regular exercise, low-income, diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease Discussion This large nationwide population-based cohort study showed an association between proteinuria and subsequent development of CIDP/MMN. Individuals with proteinuria had 2.46-fold higher risk of CIDP/MMN, which remained significant after adjustment for relevant covariates. Based on data from over 3.9 million individuals with nearly 10 years of follow-up, this study provides epidemiologic evidence of an association between proteinuria and CIDP/MMN, although the modest effect size and limited number of events warrant cautious interpretation. The biological basis of this association remains unclear, and the following considerations are presented as hypothesis-generating. Shared antigen expression in kidneys and peripheral nerves (e.g. myelin protein zero, CNTN1 and NF186), inflammatory cytokine mediated injury, and reduced erythropoietin related impairment of nerve repair may be involved [3, 21–23]. A recent cross-sectional study of 69 patients with CIDP reported that proteinuria was more frequently observed in autoimmune nodopathy than in seronegative CIDP [11]. Proteinuria has also been described in patients with anti-CNTN1 or anti-NF186 antibodies, with IgG1 and IgG4 deposition identified in the glomerular basement membrane [24]. In addition, HLA-DRB1*15 has been reported in both autoimmune nodopathy and membranous nephropathy [25, 26]. However, the results of this study should be interpreted with caution, as our study is observational and cannot establish causality. Therefore, these mechanistic considerations should be regarded as hypothesis-generating rather than explanatory. The temporal pattern observed in this study suggests that the development of CIDP/MMN was not confined to the period immediately following proteinuria detection. Rather than indicating a direct temporal link, this pattern may suggest that proteinuria serves as a marker of underlying susceptibility to CIDP/MMN. It is also possible that subclinical neuropathy was present prior to clinical diagnosis. To date, no studies have examined the relationship between MMN and proteinuria aside from reports of intravenous immunoglobulin-induced renal injury [27]. In South Korea, CIDP and MMN share the same diagnostic codes (ICD-10 code G61.8 and RID code V126). This makes it difficult to distinguish between the two conditions using administrative data. Therefore, patients diagnosed with either CIDP or MMN were analyzed collectively as CIDP/MMN. However, CIDP is estimated to be 3 to 20 times more prevalent than MMN, the most patients in this cohort were likely to have CIDP [28–33]. Further studies are needed to clarify the association between proteinuria and MMN. In subgroup analyses, neither age nor sex significantly modified the association between proteinuria and CIDP/MMN. The relative risk appeared to be higher in individuals with CKD and proteinuria. Peripheral neuropathy in CKD is commonly axonal or mixed sensorimotor polyneuropathy [34], but the risk of demyelinating neuropathy may also be increased. However, these findings should be interpreted with caution. Because subgroups had a small number of outcome events (less than 10 cases), resulting in wide confidence intervals and limited precision of the estimates. Although proteinuria in CKD has been linked to immune activation and inflammatory pathways [35], these mechanisms remain speculative and were not directly assessed in this study. This study has several limitations. First, proteinuria was assessed using a single urine dipstick test during routine health screening. This precludes distinction between transient and persistent proteinuria and relies on semi-quantitative. Although a single episode of dipstick-detected proteinuria may indicate early renal dysfunction [36], this method is less accurate than quantitative methods and may have introduced non-differential misclassification of proteinuria status, which could have led to either underestimation or overestimation of the true association. Second, the use of administrative claims data limited the ability to determine whether proteinuria was symptomatic or asymptomatic. Nevertheless, proteinuria detected in national health screening programs in South Korea is typically asymptomatic, and public awareness of its clinical significance remains low [37]. Third, although we used a combined definition based on ICD-10 and RID codes to enhance diagnostic accuracy, the misclassification cannot be excluded, and validation studies for CIDP/MMN are not performed. While ICD/RID definition has demonstrated acceptable validity in other diseases, such as cancer and inflammatory bowel disease [38, 39], validation studies for CIDP/MMN are currently lacking. Fourth, despite the large cohort size, the number of outcome events was relatively small (n = 210), which may limit statistical power and the stability of the estimates. In addition, the EPV ratio decreased to approximately 15 in the fully adjusted model, which is a borderline level of reliable estimation. This relatively low EPV ratio may impact model stability and is therefore an important limitation to consider. Fifth, residual confounding cannot be excluded. Unmeasured factors such as autoimmune diseases, infections, medications, and the severity of comorbid conditions may have influenced the associations. In addition, due to the inherent limitations of administrative claims data, detailed clinical information was not available, which may have further contributed to residual confounding. Finally, a commercial test for antibodies associated with autoimmune nodopathy is not yet available in Korea. Therefore, the precise prevalence of autoimmune nodopathy within this cohort could not be determined. In conclusion, this nationwide, population-based study suggests an association between proteinuria and an increased risk of CIDP/MMN. However, this observational finding should be interpreted with caution, considering the modest effect size and limited number of events. Further research is required to confirm this association and clarify its clinical significance.